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Abstract
Rabies is a lethal and notifiable zoonotic disease for which diagnostics have to meet the highest standards. In recent years,
an evolution was especially seen in molecular diagnostics with a wide variety of different detection methods published.
Therefore, a first international ring trial specifically designed on the use of reverse transcription polymerase chain reaction
(RT-PCR) for detection of lyssavirus genomic RNA was organized. The trial focussed on assessment and comparison of the
performance of conventional and real-time assays. In total, 16 European laboratories participated. All participants were
asked to investigate a panel of defined lyssavirus RNAs, consisting of Rabies virus (RABV) and European bat lyssavirus 1 and 2
(EBLV-1 and -2) RNA samples, with systems available in their laboratory. The ring trial allowed the important conclusion
that conventional RT-PCR assays were really robust assays tested with a high concordance between different laboratories
and assays. The real-time RT-PCR system by Wakeley et al. (2005) in combination with an intercalating dye, and the
combined version by Hoffmann and co-workers (2010) showed good sensitivity for the detection of all RABV samples
included in this test panel. Furthermore, all used EBLV-specific assays, real-time RT-PCRs as well as conventional RT-PCR
systems, were shown to be suitable for a reliable detection of EBLVs. It has to be mentioned that differences were seen in
the performance between both the individual RT-PCR systems and the laboratories. Laboratories which used more than one
molecular assay for testing the sample panel always concluded a correct sample result. Due to the markedly high genetic
diversity of lyssaviruses, the application of different assays in diagnostics is needed to achieve a maximum of diagnostic
accuracy. To improve the knowledge about the diagnostic performance proficiency testing at an international level is
recommended before using lyssavirus molecular diagnostics e.g. for confirmatory testing.
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Introduction
Rabies as a notifiable zoonotic disease is an acute, progressive
and incurable viral encephalitis which is clinically characterized by
central nervous disorders that ultimately lead to death. The disease
is caused by different Lyssavirus species of the Rhabdoviridae family
[1], with classical rabies virus (RABV) being responsible for tens of
thousands of deaths per year [2]. In Europe, alongside sylvatic
rabies in foxes, bat rabies is prevalent in a number of different bat
species, mainly caused by the European bat lyssaviruses type 1 and
2 (EBLV-1 and 2) [3]. From single rabid bats e.g. West Caucasian
bat lyssavirus (WCBV) [4] and Bokeloh bat lyssavirus (BBLV) [5]
were isolated.
Whilst ante-mortem testing is only recommended by the World
Health Organization (WHO) for rabies suspect human patients,
definite rabies diagnosis in both human and animal samples relies
on post-mortem laboratory findings. The widely accepted (post-
mortem) ‘‘gold standard’’ method of the WHO and the World
Organisation for Animal Health (OIE) is the detection of lyssavirus
antigen by the fluorescent antibody test (FAT) [6,7]. For samples
from suspected rabid animals with contact to humans or samples
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with other epidemiological relevance, virus isolation is recom-
mended as the confirmatory test for inconclusive and negative
FAT results [2]. Apart from the inevitably fatal outcome of a
rabies infection, reliable rabies diagnosis has to meet the highest
possible quality standards because in a human case patient
management can be optimized and precautions for the nursing
staff can be taken. In an animal case laboratory confirmation of
rabies via RT-PCR is on the one hand important for the
identification of new lyssavirus species. On the other hand if
human contacts occurred with this rabid animal then adequate
post exposure prophylaxis (PEP) must be initiated.
With the advance of molecular techniques, reverse transcription
polymerase chain reaction (RT-PCR) has been increasingly used
for amplification of lyssavirus RNA from sample materials.
Nowadays, numerous assays are available; for review see Dacheux
et al. (2010) [8]. However, to date, RT-PCR and other
amplification systems are not recommended for routine post-
mortem diagnosis of rabies, but may be used for epidemiological
surveys. Laboratories conducting the analysis should have
sufficient experience with the techniques in question and should
also apply strict quality control procedures [2]. Nevertheless,
especially for ante-mortem diagnosis in humans and decomposed
brain samples these techniques showed advantages over conven-
tional virological methods and in those cases may be the only
option to obtain a definite diagnosis [9–11]. In many laboratories,
PCR has already been employed as a rapid diagnostic tool in
animal rabies diagnosis in addition to the FAT with the aim to
allow early termination of initiated PEP in humans. Also PCR
offers options for further virus characterization using sequence
analysis.
For generic pan-lyssavirus approaches the hemi-nested assay
described by Heaton et al. (1997) [12] has been widely used in
daily laboratory routine. Few nested RT-PCR protocols were
developed for pan-lyssavirus detection, e.g. Echevarrı´a et al.
(2001) and Va´zquez-Moro´n et al. (2006) [13,14]. More recently,
RT-PCR systems using fluorogenic probes allowed the detection
of sequence-specific templates in real-time. One of the most widely
used lyssavirus TaqMan assays detects and differentiates RABV
from EBLV-1 and EBLV-2. Generic primers and species-specific
probes were combined within one reaction [15]. Later on, the
specificity of the RABV system was improved by changing some
nucleotides of the primers and probe [16]. Alternatively, the
Wakeley protocol [15] (named R13 by Hoffmann et al., 2010 [17])
was combined with a second set of primers and probe (R14)
downstream of R13 on the nucleoprotein gene to broaden the
diagnostic range for RABV [17]. It was also shown that using the
primers of the Wakeley protocol with SYBRH Green, which
eliminates the requirement for probes, and therefore removes
possible problems identified with specificity of the RABV-specific
probe, allowed a sensitive pan-lyssavirus detection [18] (further
assays are mentioned in Table S1 A+B [32–41]).
Newly available chemistries, reagents and procedures have
improved and standardised the detection techniques leading to
higher sensitivities and specificities. Therefore, validated RT-
PCR-based tests were proposed as alternative, confirmatory tests
also for rabies, and were suggested to be included in the OIE
Manual of Diagnostic Tests and Vaccines for Terrestrial Animals
[19]. Furthermore, molecular tools have become an important
basis for most of the notifiable and/or zoonotic viral diseases, and
lyssaviruses should not be an exclusion.
Previous ring trials focussed mainly on classical methods like
FAT and virus isolation or included only a very limited panel of
brain tissues for the RT-PCR analysis [20]. Here, we provided for
the first time a complete report on a ring trial specifically designed
for RT-PCR for the detection of lyssavirus genomic RNA, e.g.
RABV and EBLV, focussing on an assessment and comparison of
the performance of conventional and real-time RT-PCR assays
established in different European laboratories.
Materials and Methods
A panel of 28 lyssavirus samples from the virus archive of the
Friedrich-Loeffler-Institut (FLI) was selected for the trial. Either
original brain material or tissue culture supernatant after infection
of MNA cells was used (Table 1). All isolates had been tested
positive by using FAT, rabies tissue culture infection test (RTCIT)
and real-time RT-PCRs for RABV, EBLV-1 and EBLV-2
(Hoffmann et al., 2010 [17]; Freuling et al., unpublished). In
order to cover the very high genetic diversity of the different
RABV strains, the panel consisted of 26 RABV RNA samples
from different countries across the world and various isolation
years, including one log10 dilution series (L-30, L-06, L-27, L-28),
as well as one EBLV-1 (L-18) and EBLV-2 (L-24) RNA sample
each (Table 1). The extraction of the viral RNAs was performed at
the FLI using the RNeasyH kit (Qiagen, Hilden, Germany)
according to the manufacturer’s instructions and stored in RNA-
safe buffer (50 ng/ml carrier RNA (poly A homopolymer from
Qiagen, Hilden, Germany), 0.05% Tween 20 (Sigma, Munich,
Germany) and 0.05% sodium acid (NaN3) solution (Sigma,
Munich, Germany) in RNase free water) [21]. Furthermore, two
negative samples (L-07, L-25) containing water or RNA-safe buffer
were added. All samples were transferred into labelled reaction
tubes and shipped on dry ice to the 16 participating laboratories
(Table S2 A) using polystyrene boxes. To mimic influences of
transportation, one sample set was subjected to a freeze-thaw-cycle
and subsequently tested by real-time PCR (freeze-thaw control;
Table S3). Particular attention was paid to provide the same
material to all labs in good condition.
All participants were asked to investigate the complete set of 30
blinded samples in duplicate with the diagnostic PCR assays used
in their own laboratory. If possible, differentiation of the most
common species (RABV, EBLV-1, EBLV-2) was requested and
results, e.g. positive/negative for conventional and Cq values for
real-time PCRs, respectively, had to be reported using an Excel-
spread sheet. Each test was designated to the respective laboratory
(designated as A-P), and if two or more methods were performed
an additional number (A1, A2, etc.) was added. Furthermore,
additional information on the established RT-PCR assays e.g.
published or unpublished (in-house) method, RT-PCR kits used
and modifications of protocols were also requested and recorded.
Results
In summary, nine different published and five unpublished (in-
house) assays mostly targeting the nucleoprotein gene were used in
the frame of this ring trial, including real-time RT-PCR (14 labs)
as well as conventional RT-PCR (5 labs) techniques (Tables 2, 3,
and 4). These techniques comprised both two-step (n = 2) and one-
step (n = 11) RT-PCR systems. In this ring trial eleven laboratories
relied on real-time PCR only, whereas two laboratories only used
conventional techniques (Table S2 B). Three laboratories used
both techniques in parallel. For the viral RNA detection, most
laboratories (12 out of 16) performed two or more tests. For real-
time RT-PCR detection, different modified protocols (lab-
versions) of the assay published by Wakeley et al. (2005) [15]
and the assay developed by Hoffmann et al. (2010) [17] were most
frequently used (Table 2). A lab-version of the original protocol
could differ slightly by changes of the PCR kit chemistry and/or
adjustment of the temperature profile. In detail, six laboratories
A Lyssavirus Ring Trial
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used a lab-version of the Wakeley protocol (R13) alone, while in
two laboratories versions of both, the Wakeley (R13) and the
Hoffmann protocol (R14) were run separately. In three labs,
variations of the combined version (R13/14) were used as a single-
tube reaction (Table 2). Additionally, one laboratory also applied
the assay published by Orlowska et al. (2008) [22]. This assay is
also located in the nucleoprotein encoding gene and uses a nearly
identical detection region for RABV as the Wakeley assay (98
nucleotides overlap of the amplified region). Furthermore, an in-
house broad spectrum system based on detection via an
intercalating dye was used by one laboratory (G).
To rule out variability as a result of RNA extraction
methodologies, RNA was extracted prior to the shipment to the
participating laboratories. To maintain RNA stability during
transportation, samples were stored in RNA-safe buffer [21] and
shipped on dry ice. In order to confirm RNA stability after
suboptimal transportation, one sample set was subjected to a
freeze-thaw-cycle. Subsequent real-time PCR testing of this freeze-
thaw control did not reveal any noticeable increase of Cq values
(Table S3).
Real-time RT-PCR
The results of the real-time RT-PCR genome detection in the
different laboratories are summarized in Tables 2 and 3. The
individual laboratories used one to five microliter template RNA
for their real-time PCR investigations. None of the applied real-
time RT-PCR systems or runs produced false-positive results for
the negative samples but two EBLV-2 samples scored positive in
RABV-specific real-time PCRs (P2, O). Detection of viral RNA
via RABV-specific or pan-lyssavirus real-time RT-PCR often
failed for single RABV isolates (Table 2), while ten of the 30
samples (L-1, L-2, L-8, L-11, L-13, L-16, L-19, L-20, L-22 and L-
23) were always correctly detected. Some participating laborato-
ries failed to identify certain isolates, while others obtained a
positive result using lab-versions of the same published protocol
(Table 2). The system by Wakeley et al. (2005) [15] used generic
Table 1. Data description of the samples (n = 30) included into the lyssavirus panel.
Lab ID
Ring trial
number
Virus
species Genetic lineage
Year of
isolation Origin Source Host R13* R14* R13/14*
12952 L-01 RABV NEE 2001 Estonia BS fox 31.0 27.4 27.8
13091 L-02 RABV Middle east 1991 Abu Dabi BS camel 17.5 16.7 16.7
20280 L-03 RABV Arctic-like 2006 Afghanistan BS dog 15.7 no Cq 17.0
20295 L-04 RABV Middle East 2009 Iraq BS dog 17.4 12.9 13.4
13250 L-05 RABV – 1973 Chile BS human no Cq 28.8 28.8
20293 1021 L-06 RABV Middle East 2008 Iraq BS dog – – –
NTC L-07 – – – – – – – – –
13001 L-08 RABV NEE 1990 Estonia TCS raccoon 30.9 27.3 27.7
13136 L-09 RABV Africa 2 1989 Nigeria BS – 22.8 no Cq 22.9
20281 L-10 RABV Arctic-like 2006 Afghanistan BS dog 14.9 no Cq 17.3
20297 L-11 RABV Middle East 2009 Iraq BS horse 14.9 11.9 11.8
13254 L-12 RABV – 1979 Chile BS human no Cq 20.5 20.5
13213 L-13 RABV – 1981 USA TCS skunk 28.0 25.8 25.2
13044 L-14 RABV Middle-East 1990 Saudi Arabia TCS fox 20.5 19.4 19.5
13138 L-15 RABV Africa 2 1989 Nigeria BS dog – – –
20290 L-16 RABV Middle East 2008 Iraq BS cow 24.2 25.2 24.3
11164 L-17 RABV CEE 2005 Germany BS fox no Cq 23.4 23.9
EBLV-1 L-18 EBLV-1 EBLV-1a 1968 Germany BS bat – – –
20294 L-19 RABV Middle East 2008 Iraq BS dog 16.6 12.5 12.5
13078 L-20 RABV EE 1995 Bulgaria BS human 13.8 12.7 12.8
13205 L-21 RABV – 1981 USA BS raccoon – – –
20291 L-22 RABV Middle East 2008 Iraq BS dog 22.6 18.5 19.1
SAD-B19 L-23 RABV vaccine 1991 Germany TCS vaccine 18.2 19.0 18.3
EBLV-2 L-24 EBLV-2 EBLV-2a 1985 Finland BS human – – –
RSB50 L-25 – – – – – – – – –
13081 L-26 RABV – 1985 China TCS – 26.1 23.0 22.7
20293_1022 L-27 RABV Middle East 2008 Iraq BS dog – – –
20293_1023 L-28 RABV Middle East 2008 Iraq BS dog – – -
13240 L-29 RABV Eptesicus fuscus 1986 Canada BS bat no Cq 25.4 25.5
20293 L-30 RABV Middle East 2008 Iraq BS dog 16.6 12.6 13.0
dilution series is depicted in bold; NTC: no template control; BS: brain suspension; TCS: tissue culture supernatant; NEE: North Eastern Europe; CEE: Central and Eastern
Europe; EE: Eastern Europe; RABV: Rabies virus; EBLV: European Bat Lyssavirus; –: not tested;
*Cq values from previous publication [17]; no Cq: no Cq value detected; R13, R14, R13/14: R13, R14, duplex R13/14 assay by [17].
doi:10.1371/journal.pone.0058372.t001
A Lyssavirus Ring Trial
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primers either with a RABV-specific or with EBLV-1- and -2-
specific hydrolysis probes described here as broad spectrum
approach. Additionally, one lab (N1) also used a two-step
modification of the Wakeley protocol with an intercalating dye
instead of hydrolysis probes for fluorescence detection, based on
Hayman et al. (2011) [23]. This lab-version was able to detect all
positive lyssavirus samples correctly with exception of the
1.00E23 dilution step of RABV isolate 20293 (L-28). Further-
more, two results were reported as doubtful which would require
further investigations.
Taking the best scoring laboratory results for each assay (P1 for
R13, A1 and P2 for R14, O for R13/14) a combination of R13
and R14 assays (in single wells or as duplex assay) were able to
detect all rabies samples very robustly. However, sample L-29 was
not detected by any of the applied R13 assays and samples L-05,
L-12 and L-17 were unreliably detected. Samples L-09 and L-15
from Nigeria (clade Africa 2) were not detected by the R14 system
(described previously by [17]) while samples L-03, L-11 and L-21
were unreliably detected. Moreover, some samples were unreliably
detected by both assays; specifically L-03, L-09, L-10, L-15, L-21
for R14 and L-05, L-12, L-17 and L-29 for R13. Interestingly, by
Table 2. Comparative analysis of viral genome detection via real-time RT-PCR. Mean Cq values from duplicate runs.
Broad spectrum approach RABV-specific
i.h. 2) Wakeley et al., 2005 Hoffmann et al., 2010
Sample Species r, e1 r, e1+2 r (R13) r (R14) r (R13/14)
int.
dye probes probes
int.
dye probe probe probes
G ts D3 B C D1 N1 ts P1 Imod. M N2 ts A2 A1 E F1 J P2 D2 F2 O
L-01 RABV 32 32 27 28 31 37 26 32 23 34 25 27 25 27 30 25 33 27 25
L-02 RABV 24 32 25 27 29 32 24 31 27 32 24 26 23 25 28 23 29 25 24
L-03 RABV 32* fn 26 27 30 34 24 32 27 32 24 32 exp exp exp 29 30 30 25
L-04 RABV 25 fn 26 30 30 33 24 33 27 32 23 24 23 24 24 22 29 25 24
L-05 RABV 24 26 26 exp exp 30 28 exp exp exp exp 21 23 20 21 20 27 21 21
L-06 RABV (I) 30 fn 29 33 33 37 27 37 29 35 26 27 25 27 29 25 32 26 27
L-07 neg na – – – – – – – – – – – – – – – – – –
L-08 RABV 29 30 26 27 30 35 25 31 28 34 24 26 24 25 28 24 32 26 25
L-09 RABV 33 24 20 24 24 26 29 29 21 24 18 exp exp exp exp exp 26 23 20
L-10 RABV 33* 31 23 25 28 32 22 28 25 30 22 31 exp exp exp 28 29 28 23
L-11 RABV 26 30 26 29 30 34 24 32 29 33 23 25 24 24 27 23 29 24 23
L-12 RABV 15 21 21 exp exp 23 21 exp exp exp exp 14 17 15 17 13 20 15 15
L-13 RABV 25 24 18 22 23 28 18 25 20 27 17 18 17 18 19 17 23 19 18
L-14 RABV 23 fn 23 22 27 32 21 31 24 33 20 23 21 23 23 21 28 23 21
L-15 RABV fn 33 27 33 32 36 26 31 29 35 24 exp exp exp exp exp 33 31 27
L-16 RABV 22 31 25 30 30 34 25 33 26 34 24 28 25 27 29 25 32 28 25
L-17 RABV 11 24 22 exp exp 27 23 39 exp 27 22 20 21 21 23 19 27 20 20
L-18 EBLV-1 19 25 27 30 27 30 – – – – – – – – – – – – –
L-19 RABV 28 30 26 28 29 34 24 33 27 34 23 24 23 24 24 23 29 24 24
L-20 RABV 23 24 21 23 29 29 19 26 23 30 20 20 19 18 23 18 26 20 19
L-21 RABV 32 fn 21 37 fn 31 21 28 24 30 21 28 fn fn fn 27 fn fn 23
L-22 RABV 28 36 28 31 31 35 26 34 30 36 25 26 24 26 27 24 30 26 25
L-23 RABV 23 22 19 19 23 29 17 21 22 29 17 20 19 20 23 19 24 19 18
L-24 EBLV-2 23 – 22 29 25 28 – – – – – – – – – 37# – – 31#
L-25 neg 2(45) – – – – – – – – – – – – – – – – – –
L-26 RABV fn 33 25 fn ? (40) ? (43) 32 36 34 ? (41) 30 27 fn 28 fn 30 35 27 23
L-27 RABV (II) 33 fn 33 36 36 ? (40) 30 40 35 ? (39) 30 31 ? 30 30 29 36 29 30
L-28 RABV (III) 34* fn fn 39 ? (40) fn 34 fn 39 fn 33 34 fn 33 fn 32 ? (39) 34 36
L-29 RABV 25 fn exp exp exp 31 exp exp exp exp exp 18 20 19 21 17 25 19 19
L-30 RABV (0) 24 fn 26 29 29 33 24 32 27 33 24 24 23 23 27 22 29 24 24
RABV: Rabies virus; ;EBLV: European Bat Lyssavirus;neg.: negative control; 2: negative result; #: cross-reactivitiy with other Lyssavirus species; ?: doubtful result;
*doubtful result was retested; i.h.: in-house assay; dilution series (0), (I), (II), (III); 100, 1021, 1022, 1023; mod.: assay modified; r: RABV-specific detection; e1: EBLV-1
specific; e1+2: EBLV-1+22 specific; r13, r14, r13/14: R13, R14, duplex R13/14 assay by [17]; fn: false negative results; exp: expected negative results from previous
publication; ts: two-step systems; no duplicates for assays D2, D3 and M; 2) Orlowska et al., 2008 [22].
doi:10.1371/journal.pone.0058372.t002
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combining the results from laboratories A and P where R13 and
R14 versions were applied in parallel, all positive samples were
recognized correctly with a similar sensitivity to the duplex assay.
The results from laboratories O (R13/14) and P2 (R14) for
sample L-24 provide some indication for cross-reactivity of these
rabies-specific methods with EBLV-2. Although this is not a
diagnostic disadvantage, as the assay detected a positive lyssavirus
sample correctly, it highlights the issues with the use of hydrolysis
probes to differentiate Lyssavirus species.
Varying the R14 single assay with different PCR chemistries,
laboratories E and J produced identical seven false-negative
results. Using this assay with the same RT-PCR kit and the same
PCR cycler model but slightly different temperature profiles,
laboratory P (P2) yielded a better performance with lower Cq
values (1–3 cycles; except for the Chinese strain L-26) compared to
laboratory A (A1). Also, the variation of the Cq values for
individual samples between different laboratories using a lab-
version of the same assay was remarkably broad in several cases.
The assay published by Orlowska et al. (2008) [22] correctly
recognized EBLV-1 but failed to detect several RABV isolates
including the complete dilution series. Considering the retesting of
doubtful results, the two-step in-house assay applied by laboratory
G recognized 24 out of the 26 RABV isolates as well as the EBLV-
1 and EBLV-2 samples.
In general, EBLV-1 and -2 were recognized correctly by the
appropriate assays (Table 3). Only one laboratory (N3+4) obtained
a cross-reactivity with some RABV strains using a two-step variant
of the Wakeley assay [15], whereas the remaining five laboratories
Table 3. Mean quantification cycle (Cq) values of viral genome detection via EBLV-1 and EBLV-2 specific real-time RT-PCR.
Participants
Species Freuling unpublished Wakeley et al., 2005
in-house
assay
A3 A4 O1 O2 E1* E2* F3 F4 I1 I2 J1 L1 L2 M1 M2 N3 ts N4 ts P3 P4
RABV – – – – – – – – – – – – – – – – – – –
RABV – – – – – – – – – – – – – – – – – – –
RABV – – – – – – – – – – – – – – – – – – –
RABV – – – – – – – – – – – – – – – – – – –
RABV – – – – – – – – – – – – – – – 31# – – –
RABV (I) – – – – – – – – – – – – – – – – – – –
neg – – ? (32) – – – – – – – – – – – – – – – –
RABV – – – – – – – – – – – – – – – – – – –
RABV – – – – – – – – – – – – – – – – – – –
RABV – – – – – – – – – – – – – – – – – – –
RABV – – – – – – – – – – – – – – – – – – –
RABV – – – – – – – – – – – – – – – 24# - – –
RABV – – – – – – – – – – – – – – – – – – –
RABV – – – – – – – – – – – – – – – – – – –
RABV – – ? (36) – – – – – – – – – – – – – – – –
RABV – – – – – – – – – – – – – – – – – – –
RABV – – – – – – – – – – – – – – – – – – –
EBLV–1 18 – 21 – 20 – 26 – 28 – 28 24 – 26 – 31 – 20 –
RABV – – – – – – – – – – – – – – – – – – –
RABV – – – – – – – – – – – – – – – – – – –
RABV – – – – – – – – – – – – – – – – 38# – –
RABV – – – – – – – – – – – – – – – – – – –
RABV – – – – – – – – – – – – – – – – – – –
EBLV–2 – 17 ? (13) 21 – 20 – 22 – 28 18 – 25 – 24 – 29 – 17
neg – – ? (29) – – – – – – – – – – – – – – – –
RABV – – – – – – – – – – – – – – – – – – –
RABV (II) – – – – – – – – – – – – – – – – – – –
RABV (III) – – ? (25) – – – – – – – – – – – – – – – –
RABV – – – – – – – – – – – – – – – – – – –
RABV (0) – – – – – – – – – – – – – – – – – – –
RABV: Rabies virus;;EBLV: European Bat Lyssavirus;neg.: negative control; –: not applicable; #: cross–reactivitiy with other Lyssavirus species; ?: inconclusive based on
curve shape; dilution series (0), (I), (II), (III); 100, 1021, 1022, 1023;
*Hoffmann and Mu¨ller personal communication; ts: two-step systems; no duplicates for assays M1 and M2; all laboratories except J1 used separate species-specific real-
time PCRs to detect EBLV-1 or -2.
doi:10.1371/journal.pone.0058372.t003
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had no problems applying their lab-versions of the assay. Another
laboratory obtained some inconclusive results for EBLV-1
detection according to the curve shape by usage of a yet
unpublished assay (Freuling, unpublished data). Nevertheless, this
unpublished assay provided in laboratory A very robust Cq values
for the recognition of EBLV-1.
Conventional RT-PCR
The performance of five conventional RT-PCR methods for
RABV-specific detection or a broad range application is shown in
Table 4. Although most samples were correctly diagnosed, the
1000 fold dilution step of RABV isolate 20293 (L-28) was not
detected by four of the nine conducted runs. Furthermore, at least
one sample was not recognized by each of the applied methods or
classified as doubtful. Variations of the pan-lyssavirus assays
established by Heaton et al. (1997) [12], Echevarrı´a et al. (2001)
[13], and Va´zquez-Moro´n et al. (2006) [14] were able to detect
almost every RABV and EBLV isolate in this panel (Table 4).
Both, the original protocol (lab H) developed by Va´zquez-Moro´n
and co-workers (2006) [14] and a lab-version of laboratory I (I5)
generally failed to recognize the Nigerian sample L-15. In
addition, laboratory H obtained a doubtful result for the
1.00E23 dilution step of RABV isolate 20293 (L-28). Using a
one-step version of the Heaton assay [12], laboratory J (J2)
obtained one false-positive result.
Laboratory I (I7) recognized all isolates except the European
sample L-17 with a two-step version of this assay. Lab-versions of
the system by Echevarrı´a and co-workers (2001) [13] were able to
detect all isolates, with the exception of one doubtful result in each
run. Two RABV-specific assays (in-house assay based on East
Table 4. Comparison of conventional PCR systems for the detection of RABV and/or EBLV-1 and EBLV-2.
Participants
V.-M. et al., 2006 Heaton et al., 1997 Ech. et al., 2001 i.h. M/V
Sample Species Hp I3p Jp Kp, * I5pts I1p I2p I4r, 1)ts O1r O2e
L-01 RABV RABV + + + + + + fn RABV na
L-02 RABV RABV + + + + + + + RABV na
L-03 RABV RABV + + + + + + + fn 2
L-04 RABV RABV + + + + + + + RABV na
L-05 RABV RABV + + + + + + + RABV na
L-06 RABV (I) RABV + + + + + + + RABV na
L-07 neg 2 2 2 2 2 2 2 2 2 2
L-08 RABV RABV + + + + + + + RABV na
L-09 RABV RABV + + + + + + fn RABV na
L-10 RABV RABV + + + + + + + fn -
L-11 RABV RABV + + + + + + + RABV na
L-12 RABV RABV + + + + + + + RABV na
L-13 RABV RABV + + + + + + + RABV na
L-14 RABV RABV + + + + + + + RABV na
L-15 RABV fn fn + + + + ? + RABV na
L-16 RABV RABV + + + + + + + RABV na
L-17 RABV RABV + + + fn + + + RABV na
L-18 EBLV-1 EBLV1a + + + + + + 2 2 EBLV-1
L-19 RABV RABV + + + + + + fn RABV na
L-20 RABV RABV + + + + + + + RABV na
L-21 RABV RABV + + + + ? + + fn 2
L-22 RABV RABV + + + + + + + RABV na
L-23 RABV RABV + + + + + + + RABV na
L-24 EBLV-2 EBLV2a + + + + + + 2 2 EBLV-2
L-25 neg 2 2 fp 2 2 2 2 2 2 2
L-26 RABV RABV + + + + + + + RABV na
L-27 RABV (II) RABV + + + + + + + RABV na
L-28 RABV (III) RABV + fn fn + + + fn fn 2
L-29 RABV RABV + + + + + + + fn 2
L-30 RABV (0) RABV + + + + + + fn RABV na
RABV: Rabies virus; ;EBLV: European Bat Lyssavirus;neg.: negative control; +: positive genome detection; -: negative result; ?: doubtful result; i.h.: in-house assay; na: not
applicable; dilution series (0), (I), (II), (III); 100, 1021, 1022, 1023; p: detection of RABV, EBLV-1 and -2; r: RABV-specific detection; e: EBLV-specific; fp: false positive result; fn:
false negative results; ts: two-step system;
*Bourhy unpublished data; Ech. et al., 2001: [13]; M/V: [26] and [27]; V.-M. et al., 2006: [14]; 1) Ito et al., 2001 [25].
doi:10.1371/journal.pone.0058372.t004
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et al., 2001 [24]; Ito et al., 2001 [25]) applied by laboratory O and
I (O3, I6), were not able to detect five RABV isolates, respectively.
Also EBLV-specific conventional RT-PCR assays [26,27] reliably
detected EBLV-1 and -2 (Table 4).
In general, usage of different tests in parallel led to correct or at
least questionable results which would require further investiga-
tions (Table S4). There are only a few exceptions (samples L-21
and L-28) where parallel testing provided an overall false result.
Due to an overall insufficient analytical sensitivity, two laboratories
(J, N) were not able to detect the 1000 fold dilution step of RABV
isolate 20293 (L-28) using two different tests, respectively. It is
more critical that in the hands of laboratories D and F an
inadequate degree of diagnostic sensitivity led to a detection failure
for sample L-21 despite of a significant viral load.
Discussion
During the recent validation of a fluorogenic probe-based real-
time RT-PCR for RABV, it had become evident, that a single
assay was not sufficient to detect all tested RABV strains due to a
high degree of genetic diversity [17]. As a consequence, we tried
for the first time to assess how published or in-house molecular
assays are performing at different European laboratories in an
international ring trial.
The results described and discussed here revealed a relatively
high degree of divergence among the participating laboratories.
Partially, this can be explained by the diagnostic range of the
applied assays and has been highlighted in Table 2 for the R13
and R14 assay. To differentiate between a failure of the system due
to a test specificity issue according to mismatches in the primer
and/or probe region (expected negative; Hoffmann et al., 2010
[17]) or due to laboratory discrepancies (false negative), different
labellings were used. Interestingly, some samples tested positive in
one laboratory and were not detected in the other. Various reasons
could be responsible for such an unexpected pattern, e.g. quality of
extracted RNA (degradation), primers, probes, PCR machines and
used commercial real-time RT-PCR kits. In this case the use of an
internal control system could be helpful to elucidate this finding.
In previous European ring trials for rabies routine diagnosis [20]
both conventional techniques, e.g. FAT and rabies tissue culture
infection test (RTCIT), and real-time RT-PCR had been used on
brain tissues [20]. However, the diversity of lyssavirus isolates was
very limited and therefore, results are not easily comparable. In
contrast, our study was solely dedicated to assessing established
RT-PCR assays for RABV in particular. This might explain why
most laboratories (n = 11; Table S2 B) performed real-time PCR
exclusively. Alternatively, brain homogenates would be a suitable
option for the next ring trial, enabling the application of internal
control assays such as b-actin, which will aid interpretation of the
negative results, already a vital element in any diagnostic assay.
Ring trials as the one described here trigger diagnostic
laboratories to start intensive investigations on the diagnostic
quality, so that an overall improvement can be made.
A first problem that may be associated with comparing the
performance of RT-PCR assays is the stability of the RNA during
both, transport and testing. In our case, RNA degradation is
unlikely as the RNA was preserved in a special storage buffer and
shipment was done on dry ice. Furthermore, a freeze-thaw control
was used to confirm RNA stability. A similar approach proved to
be successful for a recent European classical swine fever virus
(CSFV) ring trial [28]. In the future, samples could also be spiked
with an internal control, e.g. EGFP [21] to allow for monitoring of
PCR performance. There is proven evidence that commercially
available RT-PCR test kits perform differently and can have a
substantial impact on the RT-PCR results obtained [29].
As a main conclusion the R13/14 RABV-specific real-time RT-
PCR system [17], used as a duplex assay or in combination of both
single assays, displayed the best sensitivity for RABV detection
among all applied real-time RT-PCR assays during this ring trial.
The Wakeley assay [15] performed by lab B also displayed good
results by detecting all RABVs (apart from the known issue with L-
29 and the 1.00E23 dilution (L-28)). Also, both EBLV-1 and -2
were correctly detected with the specific primers and probes. The
application of this broad spectrum assay with an intercalating dye
(N1, two-step) enabled the detection of L-29 whilst also detecting
all other samples correctly, except the 1.00E23 dilution (L-28) and
two doubtful results. It is likely that the diluted sample was not
detected due to the application of a two-step methodology because
only a proportion of the cDNA is used in the two-step assay. In
comparison to a two-step system all the available cDNA can be
used in the one-step/one-tube system.
In North America, TaqManH PCR assays for the detection of
RABV were either comparable, or they had a considerably
reduced detection limit compared to hemi-nested PCR [30,31]. In
contrast, in this ring trial, the panel of RABV strains included was
of such genetic heterogeneity, that particularly the hydrolysis-
based assays displayed problems in detecting certain strains, mostly
not belonging to the cosmopolitan variant. Therefore, in order to
overcome these problems, the parallel use of several (real-time)
RT-PCR assays in a diagnostic setting is highly recommended.
One argument against PCR diagnostics in the field of rabies,
but also in general, is the risk of contamination leading to false-
positive results. However, carry-over contamination from positive
controls can be prevented efficiently by strict quality control
procedures in place, such as using artificial positive controls [17].
In the context of this ring trial, false-positive results were not
observed, indicating high laboratory quality standards. However,
we only asked for testing extracted RNA, and therefore the RNA
extraction step could not be evaluated, both in terms of sensitivity
as well as carry-over contamination. False-negative results due to
PCR inhibition are also critical. This possibility can easily be ruled
out by the use of an internal control as performed by five of the 16
laboratories using b-actin or external heterologous control systems.
Most conventional RT-PCR methods performed satisfactorily
for RABV detection and in general were less error-prone; nearly
all samples were recognized, than the real-time PCR approaches.
Also one conventional RT-PCR assay generally failed to detect a
certain isolate (L-15) presumably according to mismatches in the
primer binding region due to viral diversity. Furthermore, there
were fewer inter-laboratory variations when individual versions of
the same assay were used. One possible explanation could be that
conventional RT-PCRs are well established in many rabies
diagnostic laboratories, whereas the implementation of real-time
RT-PCRs is an on-going process. This is a very important point,
as we would predict a similar situation with the real-time assays as
they have become more embedded and routinely applied. While
real-time RT-PCR assays could be used for rapid rabies diagnosis,
conventional RT-PCR methods will remain valuable since
sequence information can be obtained for subsequent phylogenetic
analysis. Furthermore, all applied EBLV-specific investigations,
real-time as well as conventional systems were suitable for a
reliable EBLV diagnosis, although additional studies are required,
since only single samples of each virus has been included into the
study panel.
Based on molecular techniques using any kind of PCR
diagnostics, 29 inconclusive or false negative results occurred
resulting in an overall sensitivity of 93% (70.0–100%) for RT-
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PCR. Although this may be acceptable, in total, only four of the 16
laboratories submitted 100% concordant results for RABV
diagnosis. This appears to be a very low proportion, considering
that during rabies diagnostic ring trials 90.5% and 80.5% of
participating laboratories produced satisfactory results with no
false negative results in 2009 and one false negative result in 2010,
respectively [20]. In these previous ring trials false positive results
occurred only in laboratories were also nested PCR was
performed, presumably in consequence of cross-contamination.
Furthermore, in previous ring trials the panel consisted of very few
RABV strains. The sample material consisted of brain tissue
homogenates and no dilution series was included. In general, the
analysis of the dilution series revealed differences in sensitivity
between the various approaches. Altogether, the serial dilution of
RABV isolate 20293 was detected correctly by only 53% (16 out of
30 tests) of the appropriate real-time and conventional RT-PCR
investigations. In another 30% (9 out of 30 runs) of cases all
dilution steps except the 1.00E23 dilution could be recognized.
Although a 1.00E23 dilution does not seem very critical for a
highly sensitive method, the initial undiluted sample already had
Cq values in the high twenties, indicating a low amount of viral
RNA. Thus by diluting further, some assays reached their
diagnostic limits in terms of sensitivity. However, one has to keep
in mind that false-negative results would be a major problem in
animal rabies diagnosis where a human exposure occurred
because this can cause human fatality. Thus, parallel testing is
again recommended in this case.
The overall analysis of the ring trial showed that RT-PCR could
be a very reliable diagnostic tool if assays with the broadest
diagnostic range are used and quality standards are met at each
level. Then, RT-PCR methods are probably suitable to be used in
a qualified and trained laboratory as a second diagnostic line in
parallel to traditional methods like FAT, mouse inoculation test
(MIT) and RTCIT. For this purpose, a further harmonisation and
standardisation of the individual methods e.g. by the use of
commercial RT-PCR kits as seen in the case of CSFV detection
[28] or RT-PCR trainings could help to improve the overall
performance between the individual laboratories. Moreover, the
ability to sequence an RT-PCR amplicon is extremely useful for
surveillance purposes by determining and characterising the
Lyssavirus species detected.
Here, we used a very broad and complex RNA panel to test the
assays used as much as possible. Nevertheless, this ring trial was
not intended to discredit any methodology. However, if a
laboratory involved in rabies control uses a certain established
protocol that solely recognizes the prevailing RABV variants,
problems can occur if a case of imported rabies occurs. In this
case, the molecular diagnosis needs to be as broad as possible. This
is particularly important if laboratories act as national reference
laboratories and are confronted with human rabies diagnosis. In
this case, the use of broad spectrum lyssavirus assays may be more
suitable, as no prior epidemiological information is necessary.
These reference laboratories should particularly be interested in
the realisation of further ring trials.
At the moment, neither the WHO nor the OIE have approved
molecular techniques for rabies. However, validated PCR-based
investigations are proposed to be included in the OIE Manual of
Diagnostic Tests and Vaccines for Terrestrial Animals [19]. Based
on the results obtained in this study, instead of recommending or
approving a single assay, we would finally propose that a
proficiency test including a similarly broad standard panel of
RABV and indeed other Lyssavirus species should be passed, as
performed annually through a program coordinated by the French
Agency for Food, Environmental and Occupational Health &
Safety (ANSES) [20], before a laboratory is qualified to use RT-
PCR as a complementary test in rabies routine diagnosis.
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